Table 3.
Summary of magnetofection literature.
| Author | Year | Vector | Magnetic Nanoparticles | Modifying Agent | Targeting Cell, or Tissue | TF Efficiency | Cell Viability (% of Control) | Reference |
|---|---|---|---|---|---|---|---|---|
| Kami D | 2011 | Plasmid | Iron oxide (γ-Fe2O3) | PEI max (MW: 25 k) | P19CL6 | * 82% | 100% | [107] |
| Pickard MR | 2011 | Plasmid | NeuroMag | - | Neural precursor cell | * 30% | 70% | [39] |
| Hashimoto M | 2011 | Adenovirus, Biotin | SPION | PEI, Streptoavidin | HeLa | ** 4-fold | - | [55] |
| Adenovirus, Biotin | SPION | PEI, Streptoavidin | NIH3T3 | ** 10-fold | - | |||
| Adenovirus, Biotin | SPION | PEI, Streptoavidin | Mouse embryonic brain | - | - | |||
| Biswas S | 2011 | Plasmid | Iron oxide (Fe3O4) | Aminooxy, Oxime ether | MCF-7 | ** 1425-fold | 89% | [110] |
| B González | 2011 | Plasmid | SPION | Poly(propyleneimine) dendrimers | Saos-2 osteoblasts | * 12% | 75% | [104] |
| Zhang H | 2010 | Plasmid | SPION | Branch PEI (MW: 25 k) | NIT3T3 | * 64% | 100% | [38] |
| siRNA | SPION | Branch PEI (MW: 25 k) | NIT3T3 | * 77% | 100% | |||
| Song HP | 2010 | Plasmid | PolyMag | Tat peptide | U251 | * 60% | 80% | [43] |
| Plasmid | PolyMag | Tat peptide | Rat spinal cord | ** 2-fold | - | |||
| Arsianti M | 2010 | Plasmid | Iron oxide | Branch PEI (MW: 25 k) | BHK-21 | - | 60–90% | [51] |
| Shi Y | 2010 | Plasmid | Magnetite | Hyperbranch PEI (MW: 10 k) | COS-7 | ** 13-fold | - | [45] |
| Ang D | 2010 | Plasmid | Magnetite | Branch PEI (MW: 25 k) | COS-7 | ** 6-fold | 70% | [46] |
| Tresilwised N | 2010 | Adenovirus | Iron oxide (Fe2O3, Fe3O4) | Branch PEI (MW: 25 k), Zonyl FSA fluorosurfactant | EPP85-181RDB | ** 10-fold | - | [54] |
| Namgung R | 2010 | Plasmid | SPION | PEG, Branch PEI (MW: 25 k) | HUVEC | ** 12-fold | 80% | [48] |
| Yiu HH | 2010 | Plasmid | Iron oxide (Fe3O4) | PEI (MW: 25 k), MCM48 (Silica particle) | NCI-H292 | ** 4-fold | - | [49] |
| HC Wu | 2010 | Plasmid | Magnetite | Hydroxyapatite | Rat marrow stromal cells | * 60–70% | 100% | [105] |
| Namiki Y | 2009 | Plasmid | Magnetite | Oleic acid, Phospholipid | HSC45 | ** 8-fold | - | [50] |
| siRNA | Magnetite | Oleic acid, Phospholipid | Tissue sample from gastric cancer | - | - | |||
| Kim TS | 2009 | Plasmid | PolyMag | - | Boar spermatozoa | - | - | [52] |
| Kievit FM | 2009 | Plasmid | SPION | PEI (MW: 25 k) | C6 | * 90% | 10% | [41] |
| Plasmid | SPION | PEI (MW: 25 k), Chitosan | C6 | * 45% | 100% | |||
| Plasmid | PolyMag | - | C6 | * 32% | 66% | |||
| Lee JH | 2009 | siRNA | MnMEIO | Serum albumin, PEG-RGD | MDA-MB-435-GFP | * 30% | - | [40] |
| Li Z | 2009 | Plasmid | Iron oxide | Poly-l-lysine | Lung tissue | *** 60% | - | [103] |
| Yang SY | 2008 | Plasmid | Iron oxide (Fe3O4) | Lipofectamine 2000 | He99 | - | - | [53] |
| Plasmid | Iron oxide (Fe3O4) | DOTAP:DOPE | He99 | - | - | |||
| Pan X | 2008 | Plasmid | Magnetite | Oleic acid, Branch PEI (MW: 25 k), Transferrin | KB | ** 300-fold | 92% | [102] |
| Mykhaylyk O | 2007 | Plasmid | Iron oxide (Fe2O3, Fe3O4) | Branch PEI (MW: 25 k) | H441 | * 49% | - | [42] |
| Plasmid | Iron oxide (Fe2O3, Fe3O4) | Pluronic F-127 | H441 | * 37% | - | |||
| Plasmid | Iron oxide (Fe2O3, Fe3O4) | Lauroyl sarcosinate | H441 | - | - | |||
| Plasmid | Iron oxide (Fe2O3, Fe3O4) | Branch PEI (MW: 25 k), Lauroyl sarcosinate | H441 | - | - | |||
| Morishita N | 2005 | Plasmid | Iron oxide (γFe2O3) | HVJ-E, protamine sulfate | BHK-21 | ** 4-fold | - | [47] |
| Plasmid | Iron oxide (γ-Fe2O3) | HVJ-E, heparin sulfate | Liver, BALB/c mice (8 weeks age) | ** 3-fold | - | |||
| Scherer F | 2002 | Plasmid | SPION | PEI (MW: 800 k) | NIH3T3 | ** 5-fold | - | [44] |
| Adenovirus | SPION | PEI (MW: 800 k) | K562 | ** 100-fold | - | |||
| Retrovirus | SPION | PEI (MW: 800 k) | NIH3T3 | * 20% | - | |||
| Mah C | 2002 | Adenovirus | Avidinylated magnetite | Biotunylated heparan sulfate | C12S | * 75% | - | [56] |
| Adenovirus | Avidinylated magnetite | Biotunylated heparan sulfate | Adult 129/SvJ mice | - | - | |||
indicates % of fluorescent positive cells analyzed by flow cytometric analysis.
indicates analysis by luciferase activity assay compared with control. Transfection efficiency was indicated optimal transfection condition.
indicates transfection without magnetic force.
PEI: Polyethylenimine; PEI max: Deacaylated PEI; MNP: Magnetic nanoparticle; SPION: Superparamagnetic iron oxide nanoparticle; MW: Molecular weight; TF: transfection; PolyMag: Commercial Magnetofection reagent), NeuroMag (Commercial Magnetofection reagent); HVJ-E: hemagglutinating virus of Japan-envelope; DOTAP: 1,2-dioleoyl- 3-trimethylammonium-propane; DOPE: 1,2-dioleoyl-3-sn- phosphatidyl-ethanolamine; Tat peptide: cationic cell penetrating peptide; MeMEIO: Manganese-doped magnetism-engineered iron oxide; PEG: polyethylene glycol, Zonyl FSA fluorosurfactant: Lithium 3-[2-(perfluoroalkyl)ethylthio]propionate).